Senti Biosciences
SNTI
Market cap $9.57M

2.09 USD

-0.06

2.79%

At close Nov 18, 4:00 PM EST

1 day

-2.79%

5 days

-6.70%

1 month

-8.33%

3 months

-0.95%

6 months

-44.27%

Year to date

-68.38%

1 year

-42.74%

5 years

-96.69%

10 years

-96.69%

About: Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

Employees: 48

Healthcare Biological Products, Except Diagnostic Substances

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.55% more ownership

Funds ownership: 22.72% [Q2] → 23.27% (+0.55%) [Q3]

30% less funds holding

Funds holding: 20 [Q2] → 14 (-6) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

74% less capital invested

Capital invested by funds: $9.17M [Q2] → $2.41M (-$6.76M) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 9

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for SNTI.

See Analyst Rankings

Financial journalist opinion

Neutral

GlobeNewsWire

4 days ago

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024

Neutral

GlobeNewsWire

2 months ago

Senti Bio to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, including SENTI-202, a Logic Gated off-the-shelf CAR-NK investigational cell therapy in Phase 1 clinical trials, today announced its participation at the following investor conferences: H.C.

Neutral

GlobeNewsWire

3 months ago

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –

Neutral

GlobeNewsWire

3 months ago

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (“CIRM”).

Neutral

GlobeNewsWire

4 months ago

Senti Bio Announces Reverse Stock Split

Shares expected to begin trading on split-adjusted basis on July 18, 2024 Shares expected to begin trading on split-adjusted basis on July 18, 2024

Neutral

MarketBeat

4 months ago

Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks

High volume can indicate market strength, but volume is relative. Thirty million in traded shares doesn't mean much if the average daily volume is higher.

Neutral

GlobeNewsWire

4 months ago

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

SOUTH SAN FRANCISCO, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the California Institute for Regenerative Medicines (“CIRM”) has awarded an $8 million grant to Senti Bio.

Positive

InvestorPlace

4 months ago

Why Is Senti Biosciences (SNTI) Stock Up 32% Today?

Senti Biosciences (NASDAQ: SNTI ) stock is taking off on Tuesday alongside heavy pre-market trading of the preclinical biotechnology company's shares this morning. That has more than 8.5 million shares of SNTI stock changing hands as of this writing.

Neutral

GlobeNewsWire

6 months ago

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (“AML”).

$Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia$